Kiniksa Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $0.183; its P/E ratio is 97.81; Kiniksa Pharmaceuticals is scheduled to report earnings on April 30, 2024, and the estimated EPS forecast is $-0.08. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 67.05M	$ 54.49M	$ 48.34M	$ 61.88M	$ 99.14M
Gross Profit	$ 57.96M	$ 63.77M	$ 41.31M	$ 47.65M	$ 87.58M
EBIT	$ -8.50M	$ -1.24M	$ -9.36M	$ 7.30M	$ 46.41M
EBITDA	-	$ -1.79M	$ -9.83M	$ 7.70M	$ 46.91M
Net Income Common Stockholders	$ 20.77M	$ 14.97M	$ -12.27M	$ 4.46M	$ 224.09M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 201.08M	$ 184.99M	$ 187.49M	$ 190.61M	$ 200.72M
Total Assets	$ 483.06M	$ 484.33M	$ 442.86M	$ 459.67M	$ 459.95M
Total Debt	$ 12.96M	$ 13.52M	$ 5.62M	$ 5.92M	$ 6.71M
Net Debt	$ -188.12M	$ -171.47M	$ -181.88M	$ -184.69M	$ -194.01M
Total Liabilities	$ 77.94M	$ 72.68M	$ 52.77M	$ 459.66M	$ 75.94M
Stockholders Equity	$ 405.13M	$ 411.65M	$ 390.10M	$ 396.14M	$ 384.01M
Cash Flow	-
Free Cash Flow	-	$ -3.78M	$ -4.29M	$ -11.53M	$ 62.03M
Operating Cash Flow	$ 16.99M	$ -3.74M	$ -4.27M	$ -11.58M	$ 62.05M
Investing Cash Flow	$ -12.28M	$ 35.53M	$ -37.92M	$ -42.66M	$ 19.04M
Financing Cash Flow	$ 552.00K	$ 158.00K	$ 90.00K	$ 1.19M	$ 361.00K

Currency in USD

Kiniksa Pharmaceuticals Earnings and Revenue History

Income Statement >

Kiniksa Pharmaceuticals Debt to Assets

Balance Sheet >

Kiniksa Pharmaceuticals Cash Flow

Cash Flow >

Kiniksa Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing